SCHEMBL255573

SCHEMBL255573

Cn1nc(Cl)cc(Nc2ccn(C3CN(C(=O)OC(C)(C)C)C3)n2)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 1/20 0.36
PIK3CA P42336 3/20 0.35
MTOR P42345 1/20 0.35
PRKDC P78527 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
PDE4B Q07343 1/20 0.35
USP30 Q70CQ3 1/20 0.34
POLR1A O95602 1/20 0.34
SLC34A1 Q06495 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
RET P07949 1/20 0.33
FPR2 P25090 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
STS P08842 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL173831 0.86 WDR5 (0.32)
SCHEMBL610188 0.81 BTK (0.42) PIK3CAMTORPRKDCMKNK1RET
SCHEMBL610189 0.81 BTK (0.42) PIK3CAMTORPRKDCMKNK1RET
SCHEMBL610349 0.75 DDB1 (0.51) PIK3CAMTORPRKDCMKNK1PDE4B
SCHEMBL612067 0.75 DDB1 (0.51) PIK3CAMTORPRKDCMKNK1PDE4B
SCHEMBL610780 0.75 DDB1 (0.51) PIK3CAMTORPRKDCMKNK1PDE4B
SCHEMBL608702 0.75 DDB1 (0.56) PIK3CAMTORPRKDCMKNK1MEN1
SCHEMBL10256308 0.74 WNT3A (0.48) MKNK1MEN1KMT2ANPC1LMNA
SCHEMBL16248119 0.74 CCND1 (0.36) PIK3CAMTORPRKDCMKNK1NPC1
SCHEMBL14926034 0.74 GPR119 (0.41) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975260-B2 Pyridazinones, method of making, and method of use thereof GENETECH, INC (US) 2015-03-10 US disclosed
US-20130261103-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF GENENTECH, INC. (US) 2013-10-03 US disclosed
WO-2012030990-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT, INC. (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130261103-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, TYK2, LCK P2RX3 1387/4885PIK3CA 159/4885MTOR 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.